finance.yahoo.com ·
Truist Lowers Pt Alnylam Pharmaceuticals
Topic context
This topic has been covered 265055 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedAnalyst price target revision reflects near-term revenue headwinds from payer dynamics and shipping calendar, but no fundamental change in commercial mechanism. The ATTR-CM care coordination initiative may expand patient access over time but lacks concrete revenue or cost impact. Sector: PHARMA_BIOTECH; magnitude low, confidence low.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Truist lowered PT from $515 to $505, maintains Buy.
- Q1 results expected with seasonal weakness from payer dynamics and fewer shipping weeks.
- Alnylam announced initiatives with Viz.ai and AHA to improve ATTR-CM care coordination.
Related stories
finance.yahoo.com
Ncmi Q1 2026 Earnings Transcript
economictimes.indiatimes.com
Zydus Lifesciences Shares Jump 6 on Buyback Buzz Co Announces 166 Mn Assertio Acquisition
finance.yahoo.com
Transcript Valneva Q1 2026 Earnings
finance.yahoo.com
Aytu Aytu Q3 2026 Earnings
economictimes.indiatimes.com